Information Provided By: 
Fly News Breaks for July 10, 2017
CHRS, MEDP
Jul 10, 2017 | 06:57 EDT
KeyBanc analyst Donald Hooker downgraded Medpace Holdings (MEDP) to Sector Weight ahead of the Q2 earnings report citing valuation. The analyst also believes issues at "important" client Coherus Biosciences (CHRS) could adversely impact the relationship in the near term. Hooker views 2017 as a "rocky year" and recommends "temporarily" stepping to the sidelines with respect to Medpace shares.
News For MEDP;CHRS From the Last 2 Days
MEDP
Apr 24, 2024 | 07:15 EDT
Guggenheim raised the firm's price target on Medpace to $464 from $453 and keeps a Buy rating on the shares after an EBITDA and EPS beat-and-raise was supported by "generally positive commentary" on the call. Demand remains strong and Medpace has found ways to be more efficient, meeting its demand needs with lower headcount growth, adds the analyst, who notes that management continues to expect the current environment to support accelerating revenue growth in 2025.
MEDP
Apr 24, 2024 | 06:42 EDT
MEDP
Apr 23, 2024 | 08:00 EDT
